News & Events about Allovir Inc.
TipRanks Financial Blog
1month ago
Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR Research Report) yesterday and set a price target of $20.00. The comp... Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR Research R...
Business Wire
4 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the companys 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates...
Business Wire
7 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic cell...
Business Wire
12 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK...
Shares of AlloVir, Inc. (NASDAQ:ALVR Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $5.41, but opened at $7.29. AlloVir shares last traded at $8.25, with a volume of 885,061 shares trading hands. Several equities analysts recently issued ...